

        <rss version="2.0">
         <channel>
            <title><![CDATA[Ozay Pharma: News]]></title>
            <link>http://ozaypharma.com/</link>
            <description>Ozay Pharma</description>
            <copyright>Copyright 2012 by Ozay Pharma</copyright>
    
        <item>
         <title><![CDATA[Abbott to pay $1.6 bln for Depakote marketing]]></title>
         <author><![CDATA[Ozay Pharma]]></author>
         <description><![CDATA[May 7 (Reuters) - Abbott Laboratories Inc will pay $1.6 billion to resolve civil and criminal allegations that it promoted anti-seizure drug Depakote for uses that were not approved by U.S. health regulators, the company and federal and state officials said on Monday.]]></description>
         <link><![CDATA[http://ozaypharma.com/news/99-abbott-to-pay-16-bln-for-depakote-marketing.aspx]]></link>
         <pubDate>Tue, 08 May 2012 10:24:34 GMT</pubDate>
      </item>
    
        <item>
         <title><![CDATA[Roche stops heart drug trial as data disappoint]]></title>
         <author><![CDATA[Ozay Pharma]]></author>
         <description><![CDATA[May 7 (Reuters) - Swiss drugs company Roche has ended all studies in the development of a drug targeting heart disease, which some analysts had seen as a potential blockbuster, after poor results in a late stage trial.]]></description>
         <link><![CDATA[http://ozaypharma.com/news/98-roche-stops-heart-drug-trial-as-data-disappoint.aspx]]></link>
         <pubDate>Tue, 08 May 2012 10:22:20 GMT</pubDate>
      </item>
    
        <item>
         <title><![CDATA[Akman Pharma]]></title>
         <author><![CDATA[Ozay Pharma]]></author>
         <description><![CDATA[Akman Pharma
Pharmaceutical and medical products began to provide for the world-wide price pool.
Prices world-wide suppliers of a product is no longer a quick way to query and instantly.]]></description>
         <link><![CDATA[http://ozaypharma.com/news/97-akman-pharma.aspx]]></link>
         <pubDate>Thu, 03 May 2012 18:36:58 GMT</pubDate>
      </item>
    
        <item>
         <title><![CDATA[About Arab Health 2012]]></title>
         <author><![CDATA[Ozay Pharma]]></author>
         <description><![CDATA[Ozay Fharma will participate in Arab Health Expo 2012 in Dubai.]]></description>
         <link><![CDATA[http://ozaypharma.com/news/95-about-arab-health-2012.aspx]]></link>
         <pubDate>Tue, 17 Jan 2012 10:26:57 GMT</pubDate>
      </item>
    
        <item>
         <title><![CDATA[Novartis dispute with German wholesellers widens]]></title>
         <author><![CDATA[Ozay Pharma]]></author>
         <description><![CDATA[Nov 24 (Reuters) - The conflict between Novartis and German wholesale drug sellers about delivery conditions is widening, with two more wholesalers saying on Thursday the Swiss company has stopped supplying them with pharmaceuticals products.]]></description>
         <link><![CDATA[http://ozaypharma.com/news/94-novartis-dispute-with-german-wholesellers-widens.aspx]]></link>
         <pubDate>Thu, 12 Jan 2012 12:32:34 GMT</pubDate>
      </item>
    
        <item>
         <title><![CDATA[Europe Factors-Shares to fall for 7th day on euro zone woes]]></title>
         <author><![CDATA[Ozay Pharma]]></author>
         <description><![CDATA[LONDON, Nov 25 (Reuters) - European shares are set to fall for a
seventh straight session on Friday, with a lack of progress and clear strategy
to contain the region's two-year old debt crisis and Germany's persistent
opposition to issue joint euro zone bonds hurting sentiment.	]]></description>
         <link><![CDATA[http://ozaypharma.com/news/93-europe-factors-shares-to-fall-for-7th-day-on-euro-zone-woes.aspx]]></link>
         <pubDate>Thu, 12 Jan 2012 12:31:54 GMT</pubDate>
      </item>
    
        <item>
         <title><![CDATA[Swiss stocks - Factors to watch]]></title>
         <author><![CDATA[Ozay Pharma]]></author>
         <description><![CDATA[Nov 25 (Reuters) - Swiss shares are set to open lower on Friday, in line with other European exchanges as worries over the spiralling euro zone debt crisis keeps investors on the defensive.]]></description>
         <link><![CDATA[http://ozaypharma.com/news/92-swiss-stocks-factors-to-watch.aspx]]></link>
         <pubDate>Thu, 12 Jan 2012 12:31:17 GMT</pubDate>
      </item>
    
        <item>
         <title><![CDATA[Phoenix says forces Novartis to resume drug delivery]]></title>
         <author><![CDATA[Ozay Pharma]]></author>
         <description><![CDATA[Dec 6 (Reuters) - German drugs distributor Phoenix said it won a court injunction forcing Swiss drug Novartis to resume delivery of drugs in Germany, the latest twist in a dispute over discount pricing.]]></description>
         <link><![CDATA[http://ozaypharma.com/news/91-phoenix-says-forces-novartis-to-resume-drug-delivery.aspx]]></link>
         <pubDate>Thu, 12 Jan 2012 12:30:45 GMT</pubDate>
      </item>
    
        <item>
         <title><![CDATA[Nebraska obtained execution drug legally: state official]]></title>
         <author><![CDATA[Ozay Pharma]]></author>
         <description><![CDATA[(Reuters) - Nebraska obtained its supply of a drug used in executions of death row inmates legally and executions should proceed, state Attorney General Jon Bruning said on Monday.]]></description>
         <link><![CDATA[http://ozaypharma.com/news/90-nebraska-obtained-execution-drug-legally-state-official.aspx]]></link>
         <pubDate>Thu, 12 Jan 2012 12:29:43 GMT</pubDate>
      </item>
    
        <item>
         <title><![CDATA[Consumers groups seek to stop Medco, Express Scripts deal]]></title>
         <author><![CDATA[Ozay Pharma]]></author>
         <description><![CDATA[(Reuters) - A coalition of consumer groups urged U.S. antitrust regulators on Tuesday to stop Express Scripts Inc from buying Medco Health Solutions Inc (MHS.N), arguing healthcare companies that hire pharmacy benefits managers fail to protect consumers from higher prices.]]></description>
         <link><![CDATA[http://ozaypharma.com/news/89-consumers-groups-seek-to-stop-medco-express-scripts-deal.aspx]]></link>
         <pubDate>Thu, 12 Jan 2012 12:29:02 GMT</pubDate>
      </item>
    
        <item>
         <title><![CDATA[Pharma pays up for scarce assets]]></title>
         <author><![CDATA[Ozay Pharma]]></author>
         <description><![CDATA[(Reuters) - When it comes to healthcare deals, the new motto may be "too expensive to fail."]]></description>
         <link><![CDATA[http://ozaypharma.com/news/88-pharma-pays-up-for-scarce-assets.aspx]]></link>
         <pubDate>Thu, 12 Jan 2012 12:28:14 GMT</pubDate>
      </item>
    
        <item>
         <title><![CDATA[Dako and Amgen to collaborate in development of a companion diagnostic for an Amgen investigational cancer therapy]]></title>
         <author><![CDATA[Ozay Pharma]]></author>
         <description><![CDATA[Dako, a world leading independent cancer diagnostic supplier with 45 years of experience in pathology, announced today that it has entered into a development and collaboration agreement with Amgen Inc. (Nasdaq: AMGN) to develop a diagnostic test for an Amgen cancer drug candidate targeted for a rare and deadly cancer.]]></description>
         <link><![CDATA[http://ozaypharma.com/news/87-dako-and-amgen-to-collaborate-in-development-of-a-companion-diagnostic-for-an-amgen-investigational-cancer-therapy.aspx]]></link>
         <pubDate>Thu, 12 Jan 2012 12:27:28 GMT</pubDate>
      </item>
    
        <item>
         <title><![CDATA[Cynapsus Therapeutics Inc. : Cynapsus Announces Successful Human Volunteer Pilot Proof-of-Concept Results For APL-130277, A Sublingual Thin Film Strip Drug Candidate for Parkinson's]]></title>
         <author><![CDATA[Ozay Pharma]]></author>
         <description><![CDATA[January 10, 2012
- Sublingual Thin Film Strips of  Apomorphine are for the Treatment of Motor Fluctuations in Advanced Parkinson's Disease.
 
- A confirmatory Phase 1 Bioequivalence Study followed by a Safety Study, are expected to lead to a New Drug Application by late 2013 or early 2014.]]></description>
         <link><![CDATA[http://ozaypharma.com/news/86-cynapsus-therapeutics-inc-cynapsus-announces-successful-human-volunteer-pilot-proof-of-concept-results-for-apl-130277-a-sublingual-thin-film-strip-drug-candidate-for-parkinsons.aspx]]></link>
         <pubDate>Thu, 12 Jan 2012 12:26:49 GMT</pubDate>
      </item>
    
        <item>
         <title><![CDATA[Omnicare Announces 2012 Financial Guidance]]></title>
         <author><![CDATA[Ozay Pharma]]></author>
         <description><![CDATA[COVINGTON, Ky., January 10, 2012 - Omnicare, Inc. (NYSE:OCR) today announced a component of its 2012 financial guidance.  The Company expects full-year 2012 earnings per diluted share to be in the range of $2.37 to $2.47 (excluding special items, which are described on Omnicare's website under "Supplemental Financial Data" from the "Investors" page).]]></description>
         <link><![CDATA[http://ozaypharma.com/news/85-omnicare-announces-2012-financial-guidance.aspx]]></link>
         <pubDate>Thu, 12 Jan 2012 12:25:42 GMT</pubDate>
      </item>
    
        <item>
         <title><![CDATA[WebMD scraps sale talks, warns of weak 2012]]></title>
         <author><![CDATA[Ozay Pharma]]></author>
         <description><![CDATA[(Reuters) - Popular health information website WebMD Health Corp took itself off the auction block and warned investors of lower 2012 profits as its advertisers in the drug industry pull back on spending.]]></description>
         <link><![CDATA[http://ozaypharma.com/news/84-webmd-scraps-sale-talks-warns-of-weak-2012.aspx]]></link>
         <pubDate>Thu, 12 Jan 2012 12:25:05 GMT</pubDate>
      </item>
    
        <item>
         <title><![CDATA[Pool chlorine tied to lung damage in elite swimmers]]></title>
         <author><![CDATA[Ozay Pharma]]></author>
         <description><![CDATA[(Reuters Health) - Competitive swimmers who train at indoor chlorinated swimming pools may have lung changes similar to those seen in people with mild asthma, a new study has found.]]></description>
         <link><![CDATA[http://ozaypharma.com/news/83-pool-chlorine-tied-to-lung-damage-in-elite-swimmers.aspx]]></link>
         <pubDate>Thu, 12 Jan 2012 12:24:23 GMT</pubDate>
      </item>
    
        <item>
         <title><![CDATA[OctoPlus announces agreement with leading pharmaceutical company for development of a controlled release formulation]]></title>
         <author><![CDATA[Ozay Pharma]]></author>
         <description><![CDATA[OctoPlus N.V. ("OctoPlus" or the "Company") (Euronext: OCTO), announces today that it has signed a feasibility agreement with a leading US-based pharmaceutical company, aimed at developing a controlled release formulation of the client's therapeutic compound for local delivery into joints.

The contract announced today covers initial activities in developing a controlled release formulation of an undisclosed compound using our proprietary drug delivery technology PolyActive®. If the evaluation is successful, the project may progress into a full development, manufacturing and licensing agreement. Financial terms of the current agreement are not disclosed.]]></description>
         <link><![CDATA[http://ozaypharma.com/news/82-octoplus-announces-agreement-with-leading-pharmaceutical-company-for-development-of-a-controlled-release-formulation.aspx]]></link>
         <pubDate>Thu, 12 Jan 2012 12:23:11 GMT</pubDate>
      </item>
    
        <item>
         <title><![CDATA[Moody's sees increased pressure on EU drug prices]]></title>
         <author><![CDATA[Ozay Pharma]]></author>
         <description><![CDATA[* Budget deficits point to more government-instigated cuts

* Squeeze on healthcare spending likely to spur generics]]></description>
         <link><![CDATA[http://ozaypharma.com/news/63-moodys-sees-increased-pressure-on-eu-drug-prices.aspx]]></link>
         <pubDate>Thu, 12 Jan 2012 10:33:44 GMT</pubDate>
      </item>
    
        <item>
         <title><![CDATA[Nikkei falls but 25-day average support holds]]></title>
         <author><![CDATA[Ozay Pharma]]></author>
         <description><![CDATA[]]></description>
         <link><![CDATA[http://ozaypharma.com/news/81-nikkei-falls-but-25-day-average-support-holds.aspx]]></link>
         <pubDate>Thu, 15 Dec 2011 09:50:48 GMT</pubDate>
      </item>
    
        <item>
         <title><![CDATA[Nikkei falls but 25-day average support holds]]></title>
         <author><![CDATA[Ozay Pharma]]></author>
         <description><![CDATA[]]></description>
         <link><![CDATA[http://ozaypharma.com/news/80-nikkei-falls-but-25-day-average-support-holds.aspx]]></link>
         <pubDate>Thu, 15 Dec 2011 09:50:23 GMT</pubDate>
      </item>
    
        <item>
         <title><![CDATA[Experimental diet drug keeps weight off for 2 years]]></title>
         <author><![CDATA[Ozay Pharma]]></author>
         <description><![CDATA[(Reuters Health) - An experimental diet drug seems to help some obese people shed pounds, and keep them off for two years, researchers report.]]></description>
         <link><![CDATA[http://ozaypharma.com/news/79-experimental-diet-drug-keeps-weight-off-for-2-years.aspx]]></link>
         <pubDate>Thu, 15 Dec 2011 09:49:57 GMT</pubDate>
      </item>
    
        <item>
         <title><![CDATA[U.S. cracking down on Medicare painkiller abuse]]></title>
         <author><![CDATA[Ozay Pharma]]></author>
         <description><![CDATA[(Reuters) - Health authorities are directing Medicare prescription drug plans to withhold payments for popular painkillers when they suspect patient abuse, part of a wider effort to combat fraud.]]></description>
         <link><![CDATA[http://ozaypharma.com/news/78-us-cracking-down-on-medicare-painkiller-abuse.aspx]]></link>
         <pubDate>Thu, 15 Dec 2011 09:49:24 GMT</pubDate>
      </item>
    
        <item>
         <title><![CDATA[Hong Kong shares seen lower; Chow Tai Fook prices IPO]]></title>
         <author><![CDATA[Ozay Pharma]]></author>
         <description><![CDATA[]]></description>
         <link><![CDATA[http://ozaypharma.com/news/77-hong-kong-shares-seen-lower-chow-tai-fook-prices-ipo.aspx]]></link>
         <pubDate>Thu, 15 Dec 2011 09:48:50 GMT</pubDate>
      </item>
    
        <item>
         <title><![CDATA[China's Fosun Int'l says plans $237 mln fund]]></title>
         <author><![CDATA[Ozay Pharma]]></author>
         <description><![CDATA[Dec 14 (Reuters) - China's top private conglomerate Fosun International Ltd said it will form a 1.51 billion yuan ($237.23 million) fund in Shanghai focusing on equity and debt investments in industries other than its core property, pharmaceuticals, steel and mining activities.]]></description>
         <link><![CDATA[http://ozaypharma.com/news/76-chinas-fosun-intl-says-plans-237-mln-fund.aspx]]></link>
         <pubDate>Thu, 15 Dec 2011 09:47:48 GMT</pubDate>
      </item>
    
        <item>
         <title><![CDATA[Actelion provides an update on the strategic agreement with Trophos S.A.]]></title>
         <author><![CDATA[Ozay Pharma]]></author>
         <description><![CDATA[Actelion Pharmaceuticals Ltd / Actelion provides an update on the strategic agreement with Trophos S.A. . Processed and transmitted by Thomson Reuters ONE. The issuer is solely responsible for the content of this announcement.]]></description>
         <link><![CDATA[http://ozaypharma.com/news/75-actelion-provides-an-update-on-the-strategic-agreement-with-trophos-sa.aspx]]></link>
         <pubDate>Thu, 15 Dec 2011 09:47:10 GMT</pubDate>
      </item>
    
        <item>
         <title><![CDATA[UPDATE 1-India Glenmark seeks arbitration after US co breaches pact]]></title>
         <author><![CDATA[Ozay Pharma]]></author>
         <description><![CDATA[(Adds details, background, shares)]]></description>
         <link><![CDATA[http://ozaypharma.com/news/74-update-1-india-glenmark-seeks-arbitration-after-us-co-breaches-pact.aspx]]></link>
         <pubDate>Thu, 15 Dec 2011 09:46:13 GMT</pubDate>
      </item>
    
        <item>
         <title><![CDATA[UPDATE 1-Celesio ends dispute with Novartis over discounts]]></title>
         <author><![CDATA[Ozay Pharma]]></author>
         <description><![CDATA[* Celesio says Novartis to resume deliveries on Thursday]]></description>
         <link><![CDATA[http://ozaypharma.com/news/73-update-1-celesio-ends-dispute-with-novartis-over-discounts.aspx]]></link>
         <pubDate>Thu, 15 Dec 2011 09:45:37 GMT</pubDate>
      </item>
    
        <item>
         <title><![CDATA[FDA panel backs Alexza drug with limits]]></title>
         <author><![CDATA[Ozay Pharma]]></author>
         <description><![CDATA[U.S. drug advisers recommended approving an experimental treatment from Alexza Pharmaceuticals for calming down patients with schizophrenia or bipolar disorder, but placed restrictions on how the drug should be used.]]></description>
         <link><![CDATA[http://ozaypharma.com/news/72-fda-panel-backs-alexza-drug-with-limits.aspx]]></link>
         <pubDate>Thu, 15 Dec 2011 09:44:53 GMT</pubDate>
      </item>
    
        <item>
         <title><![CDATA[Addex Scientists Discover Glucagon-like-peptide-1 (GLP-1) Induced Interaction Between GLP-1 and Gastric Inhibitory Peptide (GIP) Receptors]]></title>
         <author><![CDATA[Ozay Pharma]]></author>
         <description><![CDATA[Addex Pharmaceuticals / Addex Scientists Discover Glucagon-like-peptide-1 (GLP-1) Induced Interaction Between GLP-1 and Gastric Inhibitory Peptide (GIP) Receptors . Processed and transmitted by Thomson Reuters ONE. The issuer is solely responsible for the content of this announcement.

The Addex Allosteric Modulator Platform Enabled Breakthrough Discovery, Advancing the Understanding of GLP-1 Mediated GPCR Signaling]]></description>
         <link><![CDATA[http://ozaypharma.com/news/71-addex-scientists-discover-glucagon-like-peptide-1-glp-1-induced-interaction-between-glp-1-and-gastric-inhibitory-peptide-gip-receptors.aspx]]></link>
         <pubDate>Mon, 28 Nov 2011 10:58:24 GMT</pubDate>
      </item>
    
        <item>
         <title><![CDATA[Novartis gets EU nod for combination blood pressure pill]]></title>
         <author><![CDATA[Ozay Pharma]]></author>
         <description><![CDATA[* Novartis says combination of drugs better at lowering blood pressure

* Patients who need multiple medications now only need one pill

* Rasitrio combines aliskiren, amlodipine and hydrochlorothiazide]]></description>
         <link><![CDATA[http://ozaypharma.com/news/70-novartis-gets-eu-nod-for-combination-blood-pressure-pill.aspx]]></link>
         <pubDate>Mon, 28 Nov 2011 10:41:23 GMT</pubDate>
      </item>
    
        <item>
         <title><![CDATA[Nycomed buys distribution rights to majority of Biomeks’ product portfolio in Turkey]]></title>
         <author><![CDATA[Ozay Pharma]]></author>
         <description><![CDATA[Nycomed has entered into an agreement with a consortium of companies that effectively sees it acquire distribution rights to Biomeks’ product portfolio in Turkey. In an announcement, Nycomed said it has signed a number of agreements with various pharmaceutical companies, including Almirall S.A., Anika Therapeutics, Inc., Bionorica AG, CSL Behring and Helsinn Healthcare SA.]]></description>
         <link><![CDATA[http://ozaypharma.com/news/69-nycomed-buys-distribution-rights-to-majority-of-biomeks-product-portfolio-in-turkey.aspx]]></link>
         <pubDate>Tue, 28 Jun 2011 11:54:46 GMT</pubDate>
      </item>
    
        <item>
         <title><![CDATA[Thai trial of Sanofi's dengue vaccine "promising"]]></title>
         <author><![CDATA[Ozay Pharma]]></author>
         <description><![CDATA[The world's first trial of a dengue fever vaccine being developed by France's Sanofi Pasteur and due for release in 2014 has seen "very promising" results in Thailand, a specialist involved in the tests said on Friday.]]></description>
         <link><![CDATA[http://ozaypharma.com/news/68-thai-trial-of-sanofis-dengue-vaccine-promising.aspx]]></link>
         <pubDate>Mon, 13 Jun 2011 15:57:50 GMT</pubDate>
      </item>
    
        <item>
         <title><![CDATA[REFILE-Thai trial of Sanofi's dengue vaccine "promising"]]></title>
         <author><![CDATA[Ozay Pharma]]></author>
         <description><![CDATA[(Corrects to clarify study is efficacy trial)

By Thin Lei Win

(Reuters) - The world's first efficacy trial of a dengue fever vaccine being developed by France's Sanofi Pasteur and due for release in 2014 has seen "very promising" results in Thailand, a specialist involved in the tests said on Friday.]]></description>
         <link><![CDATA[http://ozaypharma.com/news/67-refile-thai-trial-of-sanofis-dengue-vaccine-promising.aspx]]></link>
         <pubDate>Mon, 13 Jun 2011 15:57:15 GMT</pubDate>
      </item>
    
        <item>
         <title><![CDATA[Rudd, Gates back vaccines to save children]]></title>
         <author><![CDATA[Ozay Pharma]]></author>
         <description><![CDATA[Australia will pledge A$200 million ($210 million) at an international donor conference on Monday to support a global vaccines alliance seeking to save the lives of 4 million children in poor countries by 2015.]]></description>
         <link><![CDATA[http://ozaypharma.com/news/66-rudd-gates-back-vaccines-to-save-children.aspx]]></link>
         <pubDate>Mon, 13 Jun 2011 15:56:28 GMT</pubDate>
      </item>
    
        <item>
         <title><![CDATA[MDxHealth's Methylation Based Companion Diagnostics Enables Better Personalized Treatment in Brain Cancer]]></title>
         <author><![CDATA[Ozay Pharma]]></author>
         <description><![CDATA[Data to be Presented at ASCO from RTOG 0525 International Phase III Trial of Temozolomide
  
DURHAM, NC, and LIEGE, BELGIUM - May 31, 2011 - MDxHealth SA (NYSE Euronext: MDXH), a leading molecular diagnostics company in the field of personalized cancer treatment, today announced that its MGMT test (PredictMDxTM for Brain) has demonstrated success in personalizing brain cancer treatment in a major international phase III study. The data, obtained from a Phase III study (RTOG 0525) of temozolomide will be presented at the Annual Meeting of the American Society for Clinical Oncology (ASCO, Chicago, USA, 3-7 June) by principal investigator Mark R. Gilbert, MD (University of Texas M. D. Anderson Cancer Center) on Sunday 5th June).  ]]></description>
         <link><![CDATA[http://ozaypharma.com/news/65-mdxhealths-methylation-based-companion-diagnostics-enables-better-personalized-treatment-in-brain-cancer.aspx]]></link>
         <pubDate>Mon, 13 Jun 2011 15:53:47 GMT</pubDate>
      </item>
    
        <item>
         <title><![CDATA[MDxHealth's MGMT Test Identifies Brain Cancer Patients Likely to Live Longer on Temozolomide Treatment - Phase III Data Presented at ASCO]]></title>
         <author><![CDATA[Ozay Pharma]]></author>
         <description><![CDATA[DURHAM, NC, and LIEGE, BELGIUM - June 6, 2011 - MDxHealth SA (NYSE Euronext: MDXH), a leading molecular diagnostics company in the field of personalized cancer treatment, today announced that its MGMT test (PredictMDxTM for Brain) was shown to successfully identify those recently diagnosed glioblastoma patients more likely to live longer and have a longer progression free time period following treatment with temozolomide. The data, obtained from an international Phase III study (RTOG 0525) of temozolomide, were presented last night at the Annual Meeting of the American Society for Clinical Oncology (ASCO, Chicago, USA) by principal investigator Mark R. Gilbert, MD (University of Texas M. D. Anderson Cancer Center).  ]]></description>
         <link><![CDATA[http://ozaypharma.com/news/64-mdxhealths-mgmt-test-identifies-brain-cancer-patients-likely-to-live-longer-on-temozolomide-treatment-phase-iii-data-presented-at-asco.aspx]]></link>
         <pubDate>Mon, 13 Jun 2011 15:52:59 GMT</pubDate>
      </item>
    
        <item>
         <title><![CDATA[Turkey's Erdogan promises consensus after big win]]></title>
         <author><![CDATA[Ozay Pharma]]></author>
         <description><![CDATA[(Reuters) - Turkish Prime Minister Tayyip Erdogan's AK Party has scored a resounding third consecutive election victory, but he will need to seek consensus to push ahead with a planned new constitution.]]></description>
         <link><![CDATA[http://ozaypharma.com/news/48-turkeys-erdogan-promises-consensus-after-big-win.aspx]]></link>
         <pubDate>Mon, 13 Jun 2011 15:50:47 GMT</pubDate>
      </item>
    
        <item>
         <title><![CDATA[U.S. cancer drugs shortage has doctors scrambling]]></title>
         <author><![CDATA[Ozay Pharma]]></author>
         <description><![CDATA[Cancer medicines desperately needed by sick children and adults are in short supply, undermining the ability of U.S. doctors to administer treatments, top oncologists warned this week.]]></description>
         <link><![CDATA[http://ozaypharma.com/news/62-us-cancer-drugs-shortage-has-doctors-scrambling.aspx]]></link>
         <pubDate>Mon, 13 Jun 2011 15:50:01 GMT</pubDate>
      </item>
    
        <item>
         <title><![CDATA[U.S. FDA advisory meetings through July 22]]></title>
         <author><![CDATA[Ozay Pharma]]></author>
         <description><![CDATA[THIS DIARY IS FILED AS THE FOOD AND DRUG ADMINISTRATION UPDATES ITS SCHEDULE. ALL ITEMS EDT/GMT.]]></description>
         <link><![CDATA[http://ozaypharma.com/news/61-us-fda-advisory-meetings-through-july-22.aspx]]></link>
         <pubDate>Mon, 13 Jun 2011 15:49:26 GMT</pubDate>
      </item>
    
        <item>
         <title><![CDATA[Grifols says to close Talecris buy at start of June]]></title>
         <author><![CDATA[Ozay Pharma]]></author>
         <description><![CDATA[* To begin Talecris integration after U.S. approval

* Statement indicates U.S. rubberstamp is near]]></description>
         <link><![CDATA[http://ozaypharma.com/news/60-grifols-says-to-close-talecris-buy-at-start-of-june.aspx]]></link>
         <pubDate>Mon, 13 Jun 2011 15:47:53 GMT</pubDate>
      </item>
    
        <item>
         <title><![CDATA[U.S FTC approves Grifols' plasma tie-up]]></title>
         <author><![CDATA[Ozay Pharma]]></author>
         <description><![CDATA[* U.S. regulator approves Grifols' takeover of Talecris

* $4 bln deal creates big player in blood-derived products

* FTC says three medical products at issue (Adds official confirmation, details)]]></description>
         <link><![CDATA[http://ozaypharma.com/news/59-us-ftc-approves-grifols-plasma-tie-up.aspx]]></link>
         <pubDate>Mon, 13 Jun 2011 15:43:58 GMT</pubDate>
      </item>
    
        <item>
         <title><![CDATA[DIARY-U.S. MEETINGS / DAY AHEAD]]></title>
         <author><![CDATA[Ozay Pharma]]></author>
         <description><![CDATA[ THOMSON REUTERS, Corporate Meetings for US Companies Wednesday, June 08, 2011.]]></description>
         <link><![CDATA[http://ozaypharma.com/news/58-diary-us-meetings-day-ahead.aspx]]></link>
         <pubDate>Mon, 13 Jun 2011 15:43:03 GMT</pubDate>
      </item>
    
        <item>
         <title><![CDATA[Immediate IUD use after abortion found safe]]></title>
         <author><![CDATA[Ozay Pharma]]></author>
         <description><![CDATA[Implanting an intrauterine device (IUD) in the womb immediately after an abortion, instead of waiting 2 to 6 weeks, poses few risks to the woman, according to a new study.]]></description>
         <link><![CDATA[http://ozaypharma.com/news/57-immediate-iud-use-after-abortion-found-safe.aspx]]></link>
         <pubDate>Mon, 13 Jun 2011 15:40:17 GMT</pubDate>
      </item>
    
        <item>
         <title><![CDATA[Microsoft loses U.S. Supreme Court case on patent]]></title>
         <author><![CDATA[Ozay Pharma]]></author>
         <description><![CDATA[Microsoft Corp suffered a defeat on Thursday when the Supreme Court upheld a record $290 million jury verdict against the software giant for infringing a small Canadian company's patent.]]></description>
         <link><![CDATA[http://ozaypharma.com/news/56-microsoft-loses-us-supreme-court-case-on-patent.aspx]]></link>
         <pubDate>Mon, 13 Jun 2011 15:35:44 GMT</pubDate>
      </item>
    
        <item>
         <title><![CDATA[US STOCKS-Wall St set to dip after Chinese data, scrapped IPO]]></title>
         <author><![CDATA[Ozay Pharma]]></author>
         <description><![CDATA[* Chinese export growth slows

* Ally Financial IPO delayed

* Futures off: Dow 33 pts, S&P 500 4.5 pts, Nasdaq 4.25

* For up-to-the-minute market news see [STXNEWS/US] (Adds new analyst quote, updates prices)]]></description>
         <link><![CDATA[http://ozaypharma.com/news/55-us-stocks-wall-st-set-to-dip-after-chinese-data-scrapped-ipo.aspx]]></link>
         <pubDate>Mon, 13 Jun 2011 15:31:52 GMT</pubDate>
      </item>
    
        <item>
         <title><![CDATA[US STOCKS-Futures off after Chinese trade data, scrapped IPO]]></title>
         <author><![CDATA[Ozay Pharma]]></author>
         <description><![CDATA[* Chinese export growth slows

* Ally Financial IPO delayed

* Futures off: Dow 33 pts, S&P 500 2.8 pts, Nasdaq 4.25

* For up-to-the-minute market news see [STXNEWS/US]

(Adds Pfizer price in last paragraph)]]></description>
         <link><![CDATA[http://ozaypharma.com/news/54-us-stocks-futures-off-after-chinese-trade-data-scrapped-ipo.aspx]]></link>
         <pubDate>Mon, 13 Jun 2011 15:30:01 GMT</pubDate>
      </item>
    
        <item>
         <title><![CDATA[Pfizer cleared by EU to buy Ferrosan healthcare unit]]></title>
         <author><![CDATA[Ozay Pharma]]></author>
         <description><![CDATA[U.S. drugmaker Pfizer (PFE.N) won EU regulatory clearance on Friday to acquire Danish medical services company Ferrosan's consumer healthcare business from Altor 2003 Fund Ltd.]]></description>
         <link><![CDATA[http://ozaypharma.com/news/53-pfizer-cleared-by-eu-to-buy-ferrosan-healthcare-unit.aspx]]></link>
         <pubDate>Mon, 13 Jun 2011 15:29:22 GMT</pubDate>
      </item>
    
        <item>
         <title><![CDATA[UnitedHealth enters drug benefits business]]></title>
         <author><![CDATA[Ozay Pharma]]></author>
         <description><![CDATA[UnitedHealth Group Inc (UNH.N) is pushing into managing pharmacy benefits, bucking a trend among U.S. health insurers and threatening the dominance of the three largest companies that help negotiate drug pricing.]]></description>
         <link><![CDATA[http://ozaypharma.com/news/52-unitedhealth-enters-drug-benefits-business.aspx]]></link>
         <pubDate>Mon, 13 Jun 2011 15:23:29 GMT</pubDate>
      </item>
    
        <item>
         <title><![CDATA[Patheon posts surprise Q2 loss; shares sink]]></title>
         <author><![CDATA[Ozay Pharma]]></author>
         <description><![CDATA[(Adds analysts' estimates comparison, share movement)
* Q1 loss/shr $0.09 vs est EPS $0.10

* Q1 rev down 3 pct

* Shares down 13 pct]]></description>
         <link><![CDATA[http://ozaypharma.com/news/51-patheon-posts-surprise-q2-loss-shares-sink.aspx]]></link>
         <pubDate>Mon, 13 Jun 2011 15:21:53 GMT</pubDate>
      </item>
    
        <item>
         <title><![CDATA[US SMALL/MIDCAPS-Stocks fall as worries over economy rise]]></title>
         <author><![CDATA[Ozay Pharma]]></author>
         <description><![CDATA[Small- and mid-capitalization stocks declined on Friday, as unease increased about sluggishness in the economy and the end of the Federal Reserve's stimulus, and more downside was expected.]]></description>
         <link><![CDATA[http://ozaypharma.com/news/50-us-smallmidcaps-stocks-fall-as-worries-over-economy-rise.aspx]]></link>
         <pubDate>Mon, 13 Jun 2011 15:20:17 GMT</pubDate>
      </item>
    
        <item>
         <title><![CDATA[FDA backs GSK, Valeant epilepsy drug, with limits]]></title>
         <author><![CDATA[Ozay Pharma]]></author>
         <description><![CDATA[* Firms say drug will be in U.S. pharmacies by the year end

* Say FDA backs Potiga as a controlled substance

* Final classification still under review (Adds details, quotes)]]></description>
         <link><![CDATA[http://ozaypharma.com/news/49-fda-backs-gsk-valeant-epilepsy-drug-with-limits.aspx]]></link>
         <pubDate>Mon, 13 Jun 2011 15:18:59 GMT</pubDate>
      </item>
    
        <item>
         <title><![CDATA[UnitedHealth charges into drug benefits business]]></title>
         <author><![CDATA[Ozay Pharma]]></author>
         <description><![CDATA[(Reuters) - UnitedHealth Group Inc (UNH.N) is pushing into managing pharmacy benefits, bucking a trend among U.S. health insurers and threatening the dominance of the three largest companies that help negotiate drug pricing.]]></description>
         <link><![CDATA[http://ozaypharma.com/news/47-unitedhealth-charges-into-drug-benefits-business.aspx]]></link>
         <pubDate>Mon, 13 Jun 2011 14:55:08 GMT</pubDate>
      </item>
    
        <item>
         <title><![CDATA[Methanex profit lags; co raises concern about Chile plants]]></title>
         <author><![CDATA[Ozay Pharma]]></author>
         <description><![CDATA[ethanex, which supplies methanol to major international markets in North and Latin America, Asia-Pacific and Europe, has been forced to keep three of its plants in Chile idle due to the curtailment of natural gas supply from neighbouring Argentina.]]></description>
         <link><![CDATA[http://ozaypharma.com/news/46-methanex-profit-lags-co-raises-concern-about-chile-plants.aspx]]></link>
         <pubDate>Thu, 28 Apr 2011 15:48:08 GMT</pubDate>
      </item>
    
        <item>
         <title><![CDATA[Shoppers Drug profit rises on non-pharmacy sales]]></title>
         <author><![CDATA[Ozay Pharma]]></author>
         <description><![CDATA[The company picked up market share for health, beauty and convenience products from grocers and other retailers in the quarter by offering discounts.]]></description>
         <link><![CDATA[http://ozaypharma.com/news/45-shoppers-drug-profit-rises-on-non-pharmacy-sales.aspx]]></link>
         <pubDate>Thu, 28 Apr 2011 11:40:54 GMT</pubDate>
      </item>
    
        <item>
         <title><![CDATA[Roche sales down 9 percent in first quarter]]></title>
         <author><![CDATA[Ozay Pharma]]></author>
         <description><![CDATA[ GENEVA — Swiss drug maker Roche Holding AG blamed the strength of the franc Thursday for a 9 percent year-on-year drop in first quarter sales.]]></description>
         <link><![CDATA[http://ozaypharma.com/news/44-roche-sales-down-9-percent-in-first-quarter.aspx]]></link>
         <pubDate>Thu, 14 Apr 2011 11:43:19 GMT</pubDate>
      </item>
    
        <item>
         <title><![CDATA[Alabama: Bacteria Found in Pharmacy Faucet]]></title>
         <author><![CDATA[Ozay Pharma]]></author>
         <description><![CDATA[The Alabama Department of Public Health said Thursday that a contaminated intravenous nutritional supplement that was given to nine patients who died in hospitals last month was due to a bacterial contamination in a water faucet in the pharmacy where the supplement was produced.]]></description>
         <link><![CDATA[http://ozaypharma.com/news/43-alabama-bacteria-found-in-pharmacy-faucet.aspx]]></link>
         <pubDate>Thu, 14 Apr 2011 11:40:19 GMT</pubDate>
      </item>
    
        <item>
         <title><![CDATA[Pfizer Drug Wins FDA Panel’s Backing for Pancreatic Cancer]]></title>
         <author><![CDATA[Ozay Pharma]]></author>
         <description><![CDATA[Pfizer Inc. (PFE) won a U.S. panel’s backing to expand marketing of a cancer drug for patients with the rare type of pancreatic tumor diagnosed in Apple Inc. (AAPL)’s Steve Jobs in 2004.]]></description>
         <link><![CDATA[http://ozaypharma.com/news/42-pfizer-drug-wins-fda-panels-backing-for-pancreatic-cancer.aspx]]></link>
         <pubDate>Thu, 14 Apr 2011 11:37:58 GMT</pubDate>
      </item>
    
        <item>
         <title><![CDATA[China Stocks: Baoshan Iron, China Construction, ICBC, Vanke]]></title>
         <author><![CDATA[Ozay Pharma]]></author>
         <description><![CDATA[Shares of the following companies had unusual moves in China trading. Stock symbols are in parentheses and prices are as of the 11:30 a.m. break.]]></description>
         <link><![CDATA[http://ozaypharma.com/news/41-china-stocks-baoshan-iron-china-construction-icbc-vanke.aspx]]></link>
         <pubDate>Thu, 14 Apr 2011 11:05:27 GMT</pubDate>
      </item>
    
        <item>
         <title><![CDATA[European Stock-Index Futures Fall; BHP Billiton, BP, Roche May Be Active]]></title>
         <author><![CDATA[Ozay Pharma]]></author>
         <description><![CDATA[European stock-index fell before reports on U.S. initial jobless claims and producer prices. U.S. equity futures were little changed while Asian shares advanced.]]></description>
         <link><![CDATA[http://ozaypharma.com/news/40-european-stock-index-futures-fall-bhp-billiton-bp-roche-may-be-active.aspx]]></link>
         <pubDate>Thu, 14 Apr 2011 10:19:20 GMT</pubDate>
      </item>
    
        <item>
         <title><![CDATA[Roche's First-Quarter Sales Decline 9% on Swiss Franc’s Strength, Avastin]]></title>
         <author><![CDATA[Ozay Pharma]]></author>
         <description><![CDATA[Roche Holding AG (ROG), the world’s biggest maker of cancer drugs, said first-quarter sales declined 9 percent as the Swiss franc strengthened and revenue from the Avastin tumor medicine fell.]]></description>
         <link><![CDATA[http://ozaypharma.com/news/39-roches-first-quarter-sales-decline-9-on-swiss-francs-strength-avastin.aspx]]></link>
         <pubDate>Thu, 14 Apr 2011 10:16:42 GMT</pubDate>
      </item>
    
        <item>
         <title><![CDATA[Actelion nominates pharma veterans to board]]></title>
         <author><![CDATA[Ozay Pharma]]></author>
         <description><![CDATA[(Reuters) - Actelion Ltd (ATLN.VX) is nominating two pharmaceutical industry veterans to join the board at its May 5 annual meeting as it resists calls from hedge fund Elliott Advisors to consider selling up.]]></description>
         <link><![CDATA[http://ozaypharma.com/news/38-actelion-nominates-pharma-veterans-to-board.aspx]]></link>
         <pubDate>Wed, 06 Apr 2011 12:55:42 GMT</pubDate>
      </item>
    
        <item>
         <title><![CDATA[Study finds statins reduce pneumonia death rates]]></title>
         <author><![CDATA[Ozay Pharma]]></author>
         <description><![CDATA[* Pneumonia deaths lower in patients on statins in study]]></description>
         <link><![CDATA[http://ozaypharma.com/news/37-study-finds-statins-reduce-pneumonia-death-rates.aspx]]></link>
         <pubDate>Wed, 06 Apr 2011 12:53:07 GMT</pubDate>
      </item>
    
        <item>
         <title><![CDATA[Actelion nominates pharma veterans to board]]></title>
         <author><![CDATA[Ozay Pharma]]></author>
         <description><![CDATA[* Group proposing first GSK boss, former Schering-Plough CFO]]></description>
         <link><![CDATA[http://ozaypharma.com/news/36-actelion-nominates-pharma-veterans-to-board.aspx]]></link>
         <pubDate>Wed, 06 Apr 2011 12:50:47 GMT</pubDate>
      </item>
    
        <item>
         <title><![CDATA[Jean-Pierre Garnier and Robert Bertolini nominated to join Actelion's Board]]></title>
         <author><![CDATA[Ozay Pharma]]></author>
         <description><![CDATA[Actelion Pharmaceuticals Ltd / Jean-Pierre Garnier and Robert Bertolini nominated to join Actelion's Board . Processed and transmitted by Thomson Reuters ONE. The issuer is solely responsible for the content of this announcement.]]></description>
         <link><![CDATA[http://ozaypharma.com/news/35-jean-pierre-garnier-and-robert-bertolini-nominated-to-join-actelions-board.aspx]]></link>
         <pubDate>Wed, 06 Apr 2011 11:58:18 GMT</pubDate>
      </item>
    
        <item>
         <title><![CDATA[European shares hit 4-week closing high]]></title>
         <author><![CDATA[Ozay Pharma]]></author>
         <description><![CDATA[(Reuters) - European shares edged up to their highest close in nearly four weeks on Tuesday, with energy firms gaining after further unrest in the Middle East pushed crude prices to a two-and-a-half year high.]]></description>
         <link><![CDATA[http://ozaypharma.com/news/34-european-shares-hit-4-week-closing-high.aspx]]></link>
         <pubDate>Wed, 06 Apr 2011 11:56:20 GMT</pubDate>
      </item>
    
        <item>
         <title><![CDATA[Bleeding negates benefit of J&J clot drug in study]]></title>
         <author><![CDATA[Ozay Pharma]]></author>
         <description><![CDATA[(Reuters) - Johnson & Johnson's blood clot preventer failed to benefit patients admitted to hospitals with acute illnesses, due to a surprisingly high rate of bleeding, according to results of a new late-stage trial.]]></description>
         <link><![CDATA[http://ozaypharma.com/news/33-bleeding-negates-benefit-of-jj-clot-drug-in-study.aspx]]></link>
         <pubDate>Wed, 06 Apr 2011 11:55:37 GMT</pubDate>
      </item>
    
        <item>
         <title><![CDATA[Higher bleeding risk seen in J&J, Bayer clot drug]]></title>
         <author><![CDATA[Ozay Pharma]]></author>
         <description><![CDATA[Bleeding 2 to 2.5 times higher than standard clot drug]]></description>
         <link><![CDATA[http://ozaypharma.com/news/32-higher-bleeding-risk-seen-in-jj-bayer-clot-drug.aspx]]></link>
         <pubDate>Wed, 06 Apr 2011 11:54:40 GMT</pubDate>
      </item>
    
        <item>
         <title><![CDATA[Health risks fade after hormone therapy stops]]></title>
         <author><![CDATA[Ozay Pharma]]></author>
         <description><![CDATA[(Reuters Health) - Health risks related to hormone therapy with estrogen might go away after women stop the treatments, a new study suggests.]]></description>
         <link><![CDATA[http://ozaypharma.com/news/31-health-risks-fade-after-hormone-therapy-stops.aspx]]></link>
         <pubDate>Wed, 06 Apr 2011 11:52:32 GMT</pubDate>
      </item>
    
        <item>
         <title><![CDATA[Study finds blood marker can't predict Alzheimer's]]></title>
         <author><![CDATA[Ozay Pharma]]></author>
         <description><![CDATA[(Reuters) - Scientists searching for clues to Alzheimer's have found that higher blood levels of a protein called clusterin are closely linked with the presence and severity of the brain disease, but not with the risk of developing it.]]></description>
         <link><![CDATA[http://ozaypharma.com/news/30-study-finds-blood-marker-cant-predict-alzheimers.aspx]]></link>
         <pubDate>Wed, 06 Apr 2011 11:51:51 GMT</pubDate>
      </item>
    
        <item>
         <title><![CDATA[Pneumonia death rates lower in statin users]]></title>
         <author><![CDATA[Ozay Pharma]]></author>
         <description><![CDATA[(Reuters) - Taking cholesterol-lowering statin drugs such as Pfizer's Lipitor and AstraZeneca's Crestor could help prevent people dying from pneumonia, according to a study by British scientists released on Tuesday.]]></description>
         <link><![CDATA[http://ozaypharma.com/news/29-pneumonia-death-rates-lower-in-statin-users.aspx]]></link>
         <pubDate>Wed, 06 Apr 2011 11:51:03 GMT</pubDate>
      </item>
    
        <item>
         <title><![CDATA[Novel M&A paths gain acceptance]]></title>
         <author><![CDATA[Ozay Pharma]]></author>
         <description><![CDATA[(Reuters) - Large pharmaceutical companies may be better-served focusing on unconventional acquisitions and unique uses for drugs rather than on traditional mergers that focus on gross margins and cost-savings.]]></description>
         <link><![CDATA[http://ozaypharma.com/news/28-novel-ma-paths-gain-acceptance.aspx]]></link>
         <pubDate>Wed, 06 Apr 2011 11:49:49 GMT</pubDate>
      </item>
    
        <item>
         <title><![CDATA[Dr Vicki Sato to be appointed to Galapagos' Board of Directors]]></title>
         <author><![CDATA[Ozay Pharma]]></author>
         <description><![CDATA[Mechelen, Belgium; 1 April 2011 - Galapagos NV (Euronext: GLPG) announced today that it will propose the appointment of Dr Vicki Sato to its Board of Directors at its Annual General Shareholders' Meeting on 26 April 2011.]]></description>
         <link><![CDATA[http://ozaypharma.com/news/27-dr-vicki-sato-to-be-appointed-to-galapagos-board-of-directors.aspx]]></link>
         <pubDate>Wed, 06 Apr 2011 11:46:03 GMT</pubDate>
      </item>
    
        <item>
         <title><![CDATA[MDxHealth Successfully Raises € 8.2 Million In Equity Issue]]></title>
         <author><![CDATA[Ozay Pharma]]></author>
         <description><![CDATA[DURHAM, NC, and LIEGE, BELGIUM - April 5, 2011 - MDxHealth SA (NYSE Euronext: MDXH), a leading molecular diagnostics company in the field of personalized cancer treatment, today announced that it has successfully raised approximately € 8.2 million in gross proceeds through a private placement of new shares with investors in various jurisdictions.]]></description>
         <link><![CDATA[http://ozaypharma.com/news/26-mdxhealth-successfully-raises-82-million-in-equity-issue.aspx]]></link>
         <pubDate>Wed, 06 Apr 2011 11:44:25 GMT</pubDate>
      </item>
    
        <item>
         <title><![CDATA[Pfizer unit recalls two possibly mislabeled drugs]]></title>
         <author><![CDATA[Ozay Pharma]]></author>
         <description><![CDATA[(Reuters) - Pfizer Inc's Greenstone LLC unit said on Saturday that it was voluntarily recalling two drugs in the United States because they may have been labeled incorrectly by a third-party manufacturer.]]></description>
         <link><![CDATA[http://ozaypharma.com/news/21-pfizer-unit-recalls-two-possibly-mislabeled-drugs.aspx]]></link>
         <pubDate>Thu, 31 Mar 2011 12:26:30 GMT</pubDate>
      </item>
    
        <item>
         <title><![CDATA[Bayer again included in major sustainability indices]]></title>
         <author><![CDATA[Ozay Pharma]]></author>
         <description><![CDATA[Bayer continues to be listed in the two major sustainability indices FTSE4Good and ASPI.]]></description>
         <link><![CDATA[http://ozaypharma.com/news/25-bayer-again-included-in-major-sustainability-indices.aspx]]></link>
         <pubDate>Thu, 31 Mar 2011 12:26:23 GMT</pubDate>
      </item>
    
        <item>
         <title><![CDATA[Galapagos increases share capital through warrant exercises]]></title>
         <author><![CDATA[Ozay Pharma]]></author>
         <description><![CDATA[Mechelen, Belgium; 30 March 2011 - Galapagos NV (Euronext: GLPG) announced today a capital increase arising from employee warrant exercises.]]></description>
         <link><![CDATA[http://ozaypharma.com/news/24-galapagos-increases-share-capital-through-warrant-exercises.aspx]]></link>
         <pubDate>Thu, 31 Mar 2011 12:21:23 GMT</pubDate>
      </item>
    
        <item>
         <title><![CDATA[Head-to-head eye drug results tipped for early May]]></title>
         <author><![CDATA[Ozay Pharma]]></author>
         <description><![CDATA[Lucentis vs Avastin study may feature at May 1-5 congress.
Lucentis at risk if far cheaper Avastin proves as good.
Lucentis brings in $1.5 bln/yr for both Roche and Novartis.]]></description>
         <link><![CDATA[http://ozaypharma.com/news/23-head-to-head-eye-drug-results-tipped-for-early-may.aspx]]></link>
         <pubDate>Thu, 31 Mar 2011 12:17:25 GMT</pubDate>
      </item>
    
        <item>
         <title><![CDATA[Analysis: Egyptians grapple with political overhaul]]></title>
         <author><![CDATA[Ozay Pharma]]></author>
         <description><![CDATA[(Reuters) - Egyptian protesters turned from toppling a president to rebuilding a country they feel is once again theirs and cleaning up Tahrir Square where many vowed they would stay to hold their new army rulers to account.]]></description>
         <link><![CDATA[http://ozaypharma.com/news/17-analysis-egyptians-grapple-with-political-overhaul.aspx]]></link>
         <pubDate>Thu, 31 Mar 2011 10:50:36 GMT</pubDate>
      </item>
    
        <item>
         <title><![CDATA[Egypt military says presidential election this year]]></title>
         <author><![CDATA[Ozay Pharma]]></author>
         <description><![CDATA[(Reuters) - Egypt will elect a new president by the end of the year, the ruling military council said on Wednesday, laying out more details of the political transition which Egyptians hope will produce a democratic government.]]></description>
         <link><![CDATA[http://ozaypharma.com/news/22-egypt-military-says-presidential-election-this-year.aspx]]></link>
         <pubDate>Thu, 31 Mar 2011 10:48:01 GMT</pubDate>
      </item>
    
        <item>
         <title><![CDATA[K-V shares drop on FDA's decision on Makena]]></title>
         <author><![CDATA[Ozay Pharma]]></author>
         <description><![CDATA[(Reuters) - Pharmacies face no regulatory action for producing cheap versions of K-V Pharmaceuticals' pre-term birth drug, U.S. health regulators said, sending the company's shares down more than 20 percent.]]></description>
         <link><![CDATA[http://ozaypharma.com/news/20-k-v-shares-drop-on-fdas-decision-on-makena.aspx]]></link>
         <pubDate>Thu, 31 Mar 2011 10:03:43 GMT</pubDate>
      </item>
    
        <item>
         <title><![CDATA[Rising reports of bad reactions to drugs.]]></title>
         <author><![CDATA[Ozay Pharma]]></author>
         <description><![CDATA[(Reuters Health) - Official reports of negative reactions to prescription drugs have increased dramatically over the last decade, according to a new study.]]></description>
         <link><![CDATA[http://ozaypharma.com/news/19-rising-reports-of-bad-reactions-to-drugs.aspx]]></link>
         <pubDate>Thu, 31 Mar 2011 10:02:07 GMT</pubDate>
      </item>
    
        <item>
         <title><![CDATA[Fear follows fleeing Libyans abroad]]></title>
         <author><![CDATA[Ozay Pharma]]></author>
         <description><![CDATA[(Reuters) - Sitting in a Tunis hotel lobby, a Libyan businessman just arrived from Tripoli repeatedly refuses interview requests from TV journalists to talk about events back home.]]></description>
         <link><![CDATA[http://ozaypharma.com/news/18-fear-follows-fleeing-libyans-abroad.aspx]]></link>
         <pubDate>Thu, 31 Mar 2011 09:45:04 GMT</pubDate>
      </item>
    
        <item>
         <title><![CDATA[Egyptians topple president and turn to rebuilding]]></title>
         <author><![CDATA[Ozay Pharma]]></author>
         <description><![CDATA[(Reuters) - Egyptian protesters turned from toppling a president to rebuilding a country they feel is once again theirs and cleaning up Tahrir Square where many vowed they would stay to hold their new army rulers to account.]]></description>
         <link><![CDATA[http://ozaypharma.com/news/16-egyptians-topple-president-and-turn-to-rebuilding.aspx]]></link>
         <pubDate>Thu, 31 Mar 2011 09:18:45 GMT</pubDate>
      </item>
    
        <item>
         <title><![CDATA[Colorado pharmacy mistake puts woman's pregnancy at risk]]></title>
         <author><![CDATA[Ozay Pharma]]></author>
         <description><![CDATA[(Reuters) - A Safeway Inc. pharmacist mistakenly sold a pregnant Colorado woman a powerful anti-cancer drug that may cause birth defects or miscarriages, the grocery chain said on Tuesday.]]></description>
         <link><![CDATA[http://ozaypharma.com/news/15-colorado-pharmacy-mistake-puts-womans-pregnancy-at-risk.aspx]]></link>
         <pubDate>Thu, 31 Mar 2011 09:16:06 GMT</pubDate>
      </item>
    
        <item>
         <title><![CDATA[Rising reports of bad reactions to drugs]]></title>
         <author><![CDATA[Ozay Pharma]]></author>
         <description><![CDATA[(Reuters Health) - Official reports of negative reactions to prescription drugs have increased dramatically over the last decade, according to a new study.]]></description>
         <link><![CDATA[http://ozaypharma.com/news/14-rising-reports-of-bad-reactions-to-drugs.aspx]]></link>
         <pubDate>Wed, 30 Mar 2011 18:30:22 GMT</pubDate>
      </item>
    
        <item>
         <title><![CDATA[New rule limiting prescription transfers to be reversed]]></title>
         <author><![CDATA[Ozay Pharma]]></author>
         <description><![CDATA[BY SUZANNE HOHOLIK
THE COLUMBUS DISPATCH
Soon, Ohioans will once again be able to move their prescriptions from pharmacy to pharmacy as often as they like.]]></description>
         <link><![CDATA[http://ozaypharma.com/news/13-new-rule-limiting-prescription-transfers-to-be-reversed.aspx]]></link>
         <pubDate>Wed, 30 Mar 2011 18:22:20 GMT</pubDate>
      </item>
    
        <item>
         <title><![CDATA[Three held for killing pharmacist]]></title>
         <author><![CDATA[Ozay Pharma]]></author>
         <description><![CDATA[NEW DELHI: The northeast district police has arrested three men identified as Anwar (25), Aksar (23) and Saikh Safuddin (22) for allegedly murdering a pharmacist on Friday when he unwittingly tried to intervene and stop a gang war between two rival factions in the New Seemapuri area in northeast Delhi. ]]></description>
         <link><![CDATA[http://ozaypharma.com/news/12-three-held-for-killing-pharmacist.aspx]]></link>
         <pubDate>Wed, 30 Mar 2011 18:20:00 GMT</pubDate>
      </item>
    
        </channel> </rss>
    

